Allos Therapeutics' EFAPROXYN(TM) Found to Reduce Tumor Hypoxia and HIF-1-alpha Expression in Human Breast Cancer Xenografts
05 6월 2006 - 10:00PM
PR Newswire (US)
WESTMINSTER, Colo., June 5 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH) today announced the presentation
of results from a pre- clinical study designed to assess the
effects of EFAPROXYN(TM) (efaproxiral) on tumor oxygenation and
hypoxia-inducible factor 1 (HIF-1-alpha) gene expression in a human
breast cancer xenograft. Michael E. Saunders, M.D., Vice President,
Clinical Development of Allos Therapeutics presented the findings
in a poster presentation today at the 2006 Annual Meeting of the
American Society of Clinical Oncology. In this study, investigators
injected human breast cancer cells into mice. Following tumor
development, animals were assigned to one of three treatment
groups: control, supplemental oxygen, or efaproxiral (300 mg/m2)
plus supplemental oxygen. Special tissue staining assays were
utilized to evaluate the effect of these treatments on tumor
hypoxia and HIF-1-alpha, a transcription factor that is widely
believed to play a central role in the regulation of tumor
metabolism, blood vessel formation, and growth. Results of the
analysis indicated that animals treated with efaproxiral plus
supplemental oxygen showed a statistically significant reduction in
tumor hypoxia and efaproxiral-mediated down-regulation of
HIF-1-alpha expression when compared to both the control and
supplemental oxygen treatment groups. "These findings are
interesting because up to this point, the primary focus of clinical
investigations with efaproxiral has been related to its capacity to
enhance oxygen delivery into solid tumors and sensitize tumors to
radiotherapy," said Brian Kavanagh, M.D., M.P.H., Associate
Professor and Vice-Chair, Department of Radiation Oncology,
University of Colorado Comprehensive Cancer Center, and the study's
principal investigator. "Here we not only confirm efaproxiral's
ability to reduce tumor hypoxia but also take a first step toward
looking at the key molecular signaling responses that occur as a
consequence of the extra oxygen delivery." About EFAPROXYN
EFAPROXYN is the first synthetic small molecule designed to
sensitize hypoxic, or oxygen-deprived, areas of tumors during
radiation therapy by facilitating the release of oxygen from
hemoglobin, the oxygen-carrying protein contained within red blood
cells, and increasing the level of oxygen in tumors. The presence
of oxygen in tumors is an essential element for the effectiveness
of radiation therapy. By increasing tumor oxygenation, the Company
believes that EFAPROXYN has the potential to enhance the efficacy
of standard radiation therapy. About Allos Therapeutics, Inc. Allos
Therapeutics, Inc. (NASDAQ:ALTH) is a biopharmaceutical company
focused on developing and commercializing innovative small molecule
therapeutics for the treatment of cancer. The Company's lead
product candidate, EFAPROXYN, is a synthetic small molecule
designed to sensitize hypoxic, or oxygen-deprived, tumor tissue
during radiation therapy. EFAPROXYN is currently being evaluated as
an adjunct to whole brain radiation therapy in a pivotal Phase 3
trial in women with brain metastases originating from breast
cancer. The Company's other product candidates are: PDX
(pralatrexate), a small molecule chemotherapeutic agent (DHFR
inhibitor) currently under investigation as both a single agent and
in combination therapy regimens in patients with non-small cell
lung cancer and Non-Hodgkin's lymphoma; and RH1, a small molecule
chemotherapeutic agent bioactivated by the enzyme DT-diaphorase
currently under evaluation in patients with advanced solid tumors.
For more information, visit the Company's web site at
http://www.allos.com/. Safe Harbor Statement This press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. Such forward-looking statements include statements
relating to the potential safety and efficacy of efaproxiral; the
potential for new avenues of clinical development for efaproxiral
to emerge, and other statements that are other than statements of
historical facts. In some cases, you can identify forward-looking
statements by terminology such as "may," "will," "should,"
"expects," "intends," "plans," anticipates," "believes,"
"estimates," "predicts," "projects," "potential," "continue," and
other similar terminology or the negative of these terms, but their
absence does not mean that a particular statement is not
forward-looking. Such forward-looking statements are not guarantees
of future performance and are subject to risks and uncertainties
that may cause actual results to differ materially from those
anticipated by the forward-looking statements. These risks and
uncertainties include, among others: that pre-clinical trial
designs and results may not be predictive of future clinical trial
designs or results, and that new avenues of clinical development
for efaproxiral may not emerge or we may lack the financial or
other resources necessary to pursue such opportunities. Additional
information concerning these and other factors that may cause
actual results to differ materially from those anticipated in the
forward-looking statements is contained in the "Risk Factors"
section of the Company's Annual Report on Form 10-K for the year
ended December 31, 2005 and in the Company's other periodic reports
and filings with the Securities and Exchange Commission. The
Company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release. All
forward-looking statements are based on information currently
available to the Company on the date hereof, and the Company
undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of
this presentation, except as required by law. Note: EFAPROXYN(TM)
and the Allos logo are trademarks of Allos Therapeutics, Inc.
DATASOURCE: Allos Therapeutics, Inc. CONTACT: Jennifer Neiman,
Manager, Corporate Communications of Allos Therapeutics, Inc.,
+1-720-540-5227, Web site: http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024